Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
Equillium, Inc. (EQ)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Notice of Delisting or Failure to... |
08/09/2023 |
8-K
| Quarterly results |
05/25/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
05/23/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/11/2023 |
8-K
| Quarterly results |
04/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
03/23/2023 |
8-K
| Quarterly results |
12/23/2022 |
8-K
| Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial ... |
12/14/2022 |
8-K
| Quarterly results |
12/06/2022 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results |
09/27/2022 |
8-K
| Investor presentation |
09/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"Consent of Ernst & Young LLP, independent registered public accounting firm",
"Audited consolidated financial statements of Metacrine and its subsidiary as of and for the years ended December 31, 2021 and 2020, and the unaudited interim financial statements of Metacrine and its subsidiary as of June 30, 2022 and for the six months ended June 30, 2022 and 2021",
"Unaudited pro forma condensed combined balance sheet for the Company and its subsidiaries and Metacrine and its subsidiary as of June 30, 2022 and unaudited pro forma condensed combined statements of operations and comprehensive loss for the Company and its subsidiaries and Metacrine and its subsidiary for the year ended December 31, 2021 and for the six months ended June 30, 2022",
"Updated Equillium disclosure" |
|
09/06/2022 |
8-K
| Investor presentation
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Equillium, Inc., Metacrine, Inc., Equillium Acquisition Sub, Inc., and Triumph Merger Sub, Inc",
"Equillium to Acquire Metacrine in All-Stock Transaction",
"Investor Presentation" |
|
08/15/2022 |
8-K
| Quarterly results |
05/25/2022 |
8-K
| Quarterly results |
05/12/2022 |
8-K
| Quarterly results |
05/09/2022 |
8-K
| Quarterly results |
04/25/2022 |
8-K
| Other Events Interactive Data |
03/23/2022 |
8-K
| Quarterly results |
03/04/2022 |
8-K
| Quarterly results |
03/02/2022 |
8-K
| Quarterly results |
02/16/2022 |
8-K
| Investor presentation
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED AGREEMENT AND PLAN OF MERGER by and among Equillium, Inc.; Project JetFuel Merger Sub, Inc.; Bioniz Therapeutics, Inc. and Kevin Green, as the Securityholders' Representative Dated as of February 14, 2022 TABLE OF CONTENTS PAGE SECTION 1. DESCRIPTION OF TRANSACTION 1 1.1 The Merger 1 1.2 Effect of the Merger 1 1.3 Closing; Effective Time 2 1.4 Certificate of Incorporation and Bylaws; Directors and Officers 2 1.5 Conversion of Shares 2 1.6 Treatment of Company Options. 3 1.7 Further Action 3 1.8 Closing of the Company's Transfer Books 3 1.9 Exchange/Payment 4 1.10 Post-Closing Adjust...",
"Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates",
"Corporate Presentation" |
|
11/10/2021 |
8-K
| Quarterly results |
08/10/2021 |
8-K
| Quarterly results |
07/12/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
06/14/2021 |
8-K
| Quarterly results |
06/11/2021 |
8-K
| Quarterly results |
06/10/2021 |
8-K
| Quarterly results |
06/07/2021 |
8-K
| Quarterly results |
05/28/2021 |
8-K
| Quarterly results |
05/13/2021 |
8-K
| Quarterly results |
03/30/2021 |
8-K
| Quarterly results |
03/24/2021 |
8-K
| Quarterly results |
|
|
|